Ledger.Open graph →
SEC Form D · filed July 24, 2024

Cardurion Pharmaceuticals, Inc

Offering
$260.4M
Sold
$260.4M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
BURLINGTON, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (23)

Adam Koppel · Burlington, MADirectorNicholas Downing · Burlington, MADirectorMichael Mendelsohn · Burlington, MAExec · DirectorPeter Lawrence · Burlington, MAExec · DirectorJeb Keiper · Burlington, MADirectorDaniel Lynch · Cambridge, MADirectorEmma Reeve · Burlington, MADirectorBrad Paterson · Calgary, Alberta, CanadaDirectorSandeep Kini · Edmonds, WAExec · DirectorMichael Leo · Calgary, Alberta, CanadaDirectorChris Bakker · Calgary, Alberta, CanadaExec · DirectorRyan Agresta · Edmonds, WADirectorEvan Rachlin · MENLO PARK, CADirectorEdward Mathers · Boston, MADirectorMelissa Lee · Ottawa, OHDirectorChristopher Golda · San Francisco, CAExec · DirectorMark H. Longenecker · Chicago, ILDirectorJonathan Berent · Mountain View, CADirectorJohn Kuelper · Mountain View, CAExec · DirectorEvan Rachlin · MENLO PARK, CADirectorDaniel Lynch · Waltham, MADirectorEmma Reeve · Burlington, MADirectorEdward Mathers · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗